Cancer is Striking Patients At a Younger Age: New Screening Recommendations to Know
Colon Cancer: Rising Rates Among Younger Patients
As recently reported in the New York Times, a study published by the American Cancer Society in March showed that in 2023, an estimated 153,000 people in the United States would be diagnosed with colorectal cancer. But what’s striking about the study is that it shows a 9 percent increase in cases among people under age 50.
Many colorectal surgeons, gastroenterologists, and primary care providers are now recommending screening colonoscopies starting at age 45 in men and women with no known family history of the disease or other risk factors.
At Charter Radiology, our powerful PET/CT technology is also helping physicians in the initial staging of colorectal and other cancers.
Watch Now:
Patient presented with a failed colonoscopy and was sent to Charter Radiology for a PET/CT evaluation for initial staging.
Breast Cancer Screening – Updated Recommendations
The U.S. Preventive Services Task Force in May came out with the recommendation that women should be screened for breast cancer starting at age 40, not 50, as was the previous screening recommendation. While the task force states these screenings can be every other year, the American College of Radiology (ACR) is calling for annual breast screening for women 40 and up AND even earlier screening for high-risk women.
The ACR has additional recommendations for Breast MRI:
- Women with genetics-based increased risk (including BRCA1 carriers), those with a calculated lifetime risk of 20% or more, and those exposed to chest radiation at a young age are recommended to have MRI surveillance starting at ages 25 to 30. These women should start annual mammography at ages 25 to 40, depending on type of risk.
- Women diagnosed with breast cancer prior to age 50 or with a personal history of breast cancer and dense breasts should have annual supplemental breast MRI.
Charter Radiology is a leader in performing Breast MRIs and PET/CT for breast cancer.
Watch Now:
Breast MRI and Breast PET/CT – Powerful Tools for Women at Charter Radiology
PET/CT Breast Screening
MRI Breast Screening
PSMA PET/CT – IMPORTANT UPDATE!
Charter Radiology is excited to roll out its use of Illuccix®.
Illuccix®, after radiolabeling with Ga-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- With suspected metastasis who are candidates for initial definitive therapy
- With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- For a selection of patients with metastatic prostate cancer for whom Lu177 vipivotide tetraxetan PSMA-directed therapy is indicated.
Illuccix® doses are available all day M-F and Charter Radiology is working in collaboration with Cardinal Health to provide access to the radiotracer for Saturday appointments as needed. Doses are available as early as 7:00 AM!
- Ga-68-PSMA-11 PET/CT is well tolerated.
- The safety profile of Illuccix® has been established based on three prospective studies of another formulation of gallium Ga 68 gozetotide in patients with prostate cancer.
- No serious adverse reactions were attributed to 68Ga-PSMA-11 Injection.
Charter Radiology can image patients with Medicare, BCBS, and AETNA.
Biopsy confirmed prostate adenocarcinoma, highest Gleason score 8 (4+4), rising PSA= 9.8 ng/mL. Evaluation for initial staging.
Prostate MRI demonstrates prostate cancer confirmed by Biopsy and PSMA PETCT.
Are You at Risk?
Schedule your cardiac calcium score and Coronary CT Angiography today.
Cardiac screening saves lives!
Call us today to schedule your imaging exam:
443-917-2855 or email us.
Three Convenient Charter Radiology Locations!
5005 Signal Bell Lane, Suite 102, Clarksville, MD 21029 – Take A Virtual Tour!
10700 Charter Drive, Suite 110, Columbia, MD 21044
116 Westminster Pike, Suite 104 Reisterstown, MD 21136
Ph: (443) 917-2855 | Fax: (410) 346-5775